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Abstract
Objectives Roux-en-Y gastric bypass (RYGB) is a novel therapy for diabetes. We aimed to explore the therapeutic
mechanism of RYGB.
Methods After RYGB, animal models were established, and gene expression profile of islets was assessed. Additionally,
gastrointestinal hormones were measured using enzyme-linked immunosorbent assays. Ca2+ was studied using confocal
microscopy and patch-clamp technique. The morphology of islets and beta cells was observed using optical microscopy and
electron microscopy.
Results RYGB was an effective treatment in diabetic rats. Expression profiling data showed that RYGB produced a new
metabolic environment and that gene expression changed to adapt to the new environment. The differential expression of genes
associated with hormones, Ca2+ and cellular proliferation was closely related to RYGB and diabetes metabolism. Furthermore,
the data verified that RYGB led to changes in hormone level and enhanced Ca2+ concentration changes and Ca2+ channel activity.
Morphological data showed that RYGB induced the proliferation of islets and improved the function of beta cells.
Conclusions RYGB promoted a new metabolic environment while triggering changes to adapt to the new environment.
These changes promoted the cellular proliferation of islets and improved the function of beta cells. The quantity of beta cells
increased, and their quality improved, ultimately leading to insulin secretion enhancement.
Keywords Roux-en-Y gastric bypass . Islets . Insulin . Beta
cells . Gene expression profile
Introduction
Diabetes has become an epidemic disease in the twenty-first
century. The International Diabetes Federation estimated
that the global diabetes prevalence was 285 million in
2010.1 Moreover, over 4 million people die due to compli-
cations associated with the disease every year. Although
initiatives should be pursued to prevent the onset of type 2
diabetes, effective treatment must be available for people
who develop type 2 diabetes.2 Traditional treatment modal-
ities for diabetes do not satisfactorily control the disease or
its complications,3 and current emerging treatments remain
in the exploratory or extension phase. Therefore, discover-
ing new treatments has been the focus of considerable
medical research. Roux-en-Y gastric bypass (RYGB) is a
novel approach among the available bariatric surgery pro-
cedures and has been utilized in type 2 diabetes with a good
outcome,4,5 but the therapeutic mechanisms have remained
unclear, and various hypotheses have been debated.6–9 Sur-
gical indication has been restricted, and the surgical efficacy
is not completely satisfactory.10 Therefore, studying the
mechanism through which RYGB alleviates type 2 diabetes
is a critical theoretical and clinical research endeavor. Our
study explored the therapeutic mechanism of RYGB in
diabetes using an animal model. In this study, we investi-
gated the impact of RYGB on not only diabetic rats but also
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healthy rats. By analyzing the similarities and differ-
ences in the impact of RYGB on diabetic rats and
healthy rats, we found that RYGB promoted the cellu-
lar proliferation of islets and improved the function of




Five-week-old male Wistar and Goto-Kakizaki rats were
purchased from SLAC Laboratory Animals Co. Ltd.
(Shanghai, China). Wistar rats were chosen as the
healthy rat model, and Goto-Kakizaki rats were chosen
as the non-obese type 2 diabetic rat model. Goto-
Kakizaki rats are spontaneous diabetic rats that were
developed by the selective inbreeding of Wistar rats.11,12
All rats were treated according to the approved proto-
cols of the Tsinghua University Animal Care and Use
Committee. Wistar rats (n=20) were randomly assigned
to a control cohort of healthy rats (WT, n=10) or an
operation cohort of healthy rats (WTO, n=10). Goto-
Kakizaki rats (n=20) were also randomly assigned to a
control cohort of type 2 diabetic rats (GK, n=10) or an
operation cohort of type 2 diabetic rats (GKO, n=10).
After the rats had adapted to the environment for
1 week, the operation cohorts underwent RYGB.13–15
The rats were anesthetized with 1 % pentobarbital sodi-
um (30 mg/kg) through intraperitoneal injection. The
RYGB procedure included several key steps. (1) Ap-
proximately 20 % of the original gastric volume was
preserved. (2) The distal jejunum was connected via an
end-to-end anastomosis to the preserved stomach after
the jejunum was transected 8 cm distal to the ligament
of Treitz. (3) The proximal jejunum was connected via
an end-to-side anastomosis to the jejunum 10 cm distal
to the gastrojejunal anastomosis.
Pancreatic Islet Isolation and Beta Cell Culture
1. Pancreatic islet isolation: The rats were dissected
4 weeks after RYGB, and the islets were isolated. First,
the pancreaticobiliary duct was retrograde intubated and
clamped. Next, 10 ml collagenase V was infused in the
duct. Then, the pancreas was resected and digested for
25 min. After the digestion was terminated, single islets
were isolated under a stereomicroscope.16
2. Beta cell culture: The islets were collected in a centri-
fuge tube, and a 3-ml trypsin solution was added. Then,
the centrifuge tube was gently shaken for 3 min. Next,
1 ml of media was added to the tube. The centrifuge
tube was centrifuged at 500 rpm for 5 min. Then, the
supernatant was removed. Finally, 2 ml of culture me-
dium was added to the centrifuge tube. The medium
containing 60–70 % beta cells was transferred to a dish,
and the cells were cultured in an incubator.
Measurement of Blood Glucose, Food Intake, and Body
Weight
At 4 weeks after RYGB, the rats were fasted for 6 h,
their blood glucose was measured by the electrochemi-
cal method, and their body weight was measured using
an electronic balance. The 24-h spontaneous food intake
of rats was measured on three consecutive days using
an electronic balance 4 weeks after RYGB.
Expression Profiling
All GeneChips were processed at the CapitalBio Corpo-
ration (Beijing). For gene expression analyses, a total of
600 (60 islets/rat, n=10) freshly isolated islets were col-
lected from each cohort. First, total RNA was extracted
from each cohort sample using Trizol reagent. Then, the
RNA concentration was estimated by measuring the ab-
sorbance at 260 nm. The RNA quality was verified by
electrophoresis on ethidium bromide-stained 1.5 % aga-
rose gels and A260 nm/A280 nm ratios >1.8. A total of
500 ng of total RNA was synthesized as the transcription
cRNA probe in vitro using the BioArray ™ High Yield ™
RNA Transcript Labeling Synthesis Kit (Affymetrix)
according to the manufacturer’s instructions. Next, hy-
bridizations were set up. cDNA targets labeled with Cy5
(experimental) and Cy3 (reference) were combined and
hybridized to microarrays for 14 to 18 h (overnight) at
42 °C. Following hybridization and washing, the mem-
branes were scanned using a Storm 840 Scanner (Molec-
ular Dynamics).17 Differentially expressed genes were
selected based on an analysis of the fold change. The
selection criteria for differentially expressed genes includ-
ed a log ratio ≥2.0 for an upregulated gene and a log
ratio ≤0.5 for a downregulated gene. The molecular func-
tion and biological processes of differentially expressed
genes were analyzed using Molecule Annotation System
3.0 (MAS 3.0). The Gene Chip Rat Genome 230 2.0
Array was purchased from Affymetrix (USA).
Measurement of Hormone Levels
At 4 weeks after RYGB, hormone levels were measured
at room temperature using ELISA kits and a multilabel
reader (EnVision, PerkinElmer). After the rats were fasted
for 6 h, blood was collected from the orbital venous plexus.
The tubes for blood samples of glucagon-like peptide 1 (GLP-
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1) contained 10 μl dipeptidyl dipeptidase IV inhibitor. After
blood samples stood for 30 min, the tubes were centrifuged to
obtain the serum, and the hormone levels were measured. Rat
insulin, ghrelin, and active GLP-1 (7–36) ELISA kits were
purchased from Millipore (Billerica MA, USA).
Measurement of Intracellular Calcium and Insulin
Concentration
At 4 weeks after RYGB, the fluorescence intensities of beta
cells were measured using confocal microscopy (Zeiss 710
META, GER).18 The cells were seeded in a dish 1 day
before the experiment. After loading the cells with 2 μmol/L
fluo-4/AM and 2 μmol/L FITC in RPMI-1640 for 30 min,
they were washed three times with Hanks solution. Then,
the cells were bathed in RPMI-1640 with 8 mmol/L glucose
solution, and measurements were obtained. Beta cells
showed red fluorescence in the FITC channel and green
fluorescence in the fluo-4/AM channel. The Ca2+ and insu-
lin fluorescence intensities were recorded at 20-s intervals
400 s after fluorescence intensity stabilization. F0 was the
initial value of fluorescence intensity after fluorescence
intensity stabilization. Changes in the Ca2+ and insulin
fluorescence intensity (ΔF) were calculated using the fol-
lowing equation: ΔF=Fn−Fn−1. Axio Vision Rel.4.7 soft-
ware was used to analyze the images of the cells.
Electrophysiology of Calcium Channels
At 4 weeks after RYGB, whole-cell patch-clamping was
performed at room temperature using an EPC-10 patch-
clamp amplifier and PatchMaster software (HEKA, Germa-
ny). Beta cells grown in vitro were perfused with a standard
external solution containing the following (in millimoles per
liter): 120 NaCl, 3 D-glucose, 1 MgCl2, 4 CsCl, 20 TEA.CL,
2.5 CaCl2, and 10 Hepes, with the osmolarity adjusted to
approximately 310 mOsm (pH 7.4). This solution was further
supplemented with 1 μmol/L tetrodotoxin and 100 μmol/L
DIDS. The patch pipettes were pulled from borosilicate glass
and fire polished. The pipette resistance ranged between 3 and
5 MΩ after they were filled with the intracellular solution for
voltage-dependent calcium channels (VDCCs) to deplete cal-
cium stores and induce stored operated calcium (SOC) influx.
The intracellular solution contained the following (in milli-
moles per liter): 10 Hepes, 125 CsCl, 1 MgCl2. 10 EGTA
(pH 7.2) , and 2 μmol/LTG. In all whole-cell experiments, the
recording began with a series of resistance values below
20 MΩ. Cells with a capacitance of >5 PF and a diameter of
11–12 μm were most likely to be pancreatic beta cells.19
Voltage-dependent currents were corrected for linear leakage
and residual capacitance using on-line P/n subtraction. The
beta cells were held at −70 mV. For the normalized current
recordings, the peak currents were measured at 0 mV. For the
detection of SOC influx, voltage ramps of 100 ms spanning a
range of −100 to 100 mV were delivered from a holding
potential of 0 mV every 2 s over 600–1,000 s. A maximal
current of −100 mV was used for the statistical analysis.20 All
voltages were corrected for a liquid-junction potential of
13 mV. Capacitance currents were determined and automati-
cally compensated for using the EPC-10 amplifier. Data were
analyzed using IGOR Pro 6.20 (Wavemetrics, USA).
Morphology Techniques
1. At 4 weeks after RYGB, small samples of fresh pancre-
atic tissue were collected from the pancreas of each rat.
Then, the pancreatic tissue was fixed, embedded in
paraffin, and continuously cut into 5-μm sections. After
sections that were a certain distance apart were selected,
the sections were stained with HE and imaged with light
microscopy (IX71-A12FL/PH Olympus, Japan).
2. At 4 weeks after RYGB, a total of 300 (30 islets/rat, n=
10) freshly isolated islets were isolated from each cohort
and conventionally fixed. Then, the islets were
dehydrated in ethanol, embedded in Epon-Araldite,
strained with toluidine blue, and cut into ultrathin sec-
tions. The samples were observed with transmission
electron microscopy (Hitachi 7650, Japan).21 Image-
Pro PluS6.0 software was used to analyze the images.
Reagents
Collagenase V, FITC, trypsin, and Trizol were purchased from
Sigma (USA). Fluo-4/AM was purchased from Invitrogen
(USA). Thapsigargin was purchased from Merck (GER).
Statistical Analysis
Measurement data were expressed as the mean±SD, and
count data were expressed as percentage differences.
The data were analyzed with a repeated-measures one-
way ANOVA. P<0.05 was considered statistically sig-
nificant. All statistical analyses were performed using
SPSS 18.0 statistical software.
Results
Effect of RYGB on Correlated Metabolic Parameters
To evaluate whether the RYGB animal models met the exper-
imental requirements, several basic metabolic parameters
(blood glucose, serum insulin, body weight, and food intake)
were measured 4 weeks after RYGB. First, comparing the GK
cohort with the WT cohort, the blood glucose levels and food
intake were higher in the GK cohort; however, the body
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Table 1 Effect of RYGB on correlated metabolic parameters
WT WTO GK GKO
Glucose (mmol/L) 6.39±0.81 6.05±0.85 23.36±3.42** 10.53±1.41*
Food intake (g/d) 25.32±1.34 24.01±1.33 27.23±1.23** 24.81±1.03*
Body weight (g) 370.00±4.29 364.20±3.01 355.70±9.04** 360.70±2.87
Insulin (ng/ml) 2.12±0.33 5.23±0.83*** 1.20±0.25** 1.89±0.19****
Values represent the mean±SD of n=10
*P<0.01, significant difference between GKO and GK; **P<0.01, significant difference between WT and GK; ***P<0.01, significant difference
between WTO and WT; ****P<0.05, significant difference between GKO and GK
Fig. 1 Effect of RYGB on the gene expression of islets. a Differentially
expressed genes in islets were screened by fold analysis. Red plots indicate
relatively increased expression (log ratio ≥2.0), black indicates median
expression, and green indicates decreased expression (log ratio ≤0.5). b
Pie chart of GO mapping illustrates the biological process, molecular
function, and cellular component of the differentially expressed genes.
Comparing the operation cohorts with the control cohorts, 685 differentially
expressed genes were identified. The differentially expressed genes were
analyzed using theMolecule Annotation System, and biological regulation-
, regulation of biological process-, andmetabolism-related genes accounted
for a large proportion (up to 49.6 %). Thus, these differentially expressed
genes were mainly associated with metabolic regulation. GO mapping
suggested that the RYGB procedure led to the creation of a new metabolic
environment, and the expression of genes that were primarily related to
metabolic regulation was adjusted to adapt to the new metabolic environ-
ment. cVenn diagram of the differentially expressed genes according to the
RYGB procedure and diabetes metabolism. The circle with “519” in-
dicates 519 differentially expressed genes between WTO and WT, and
the circle with “158” indicates 158 differentially expressed genes between
GKO and GK. The intersection of the two circles with “30” indicates that
the 30 genes were the result of RYGB. The circle with “469” indicates 469
differentially expressed genes between GK andWT. The intersection of the
three circles with “13” indicates that 13 genes were closely related to the
RYGB procedure and diabetes metabolism
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weight and serum insulin were lower in the GK cohort
(Table 1). The data showed that the diabetic rats showed
symptoms of diabetes. Then, comparing the GKO cohort
with the GK cohort, the blood glucose levels and food
intake were lower, and the serum insulin was higher in
the GKO cohort, but body weight did not change
significantly. The metabolic parameters in the WTO
cohort were similar to the WT cohort, except for an
increase in serum insulin in the WTO cohort (Table 1).
RYGB was observed to alleviate type 2 diabetes in
diabetic rats and had little effect on the correlated
metabolic parameters in healthy rats 4 weeks after
Table 2 Effect of Roux-en-Y gastric bypass on hormone levels
WT WTO GK GKO
Ghrelin (ng/ml) 2.62±0.08 1.88±0.08*** 4.71±0.17** 2.83±0.16*
GLP-1 (pM) 11.62±1.54 15.67±1.14*** 7.15±0.95** 18.56±1.75*
Values represent the mean±SD of n=10
*P<0.01, significant difference between GKO and GK; **P<0.01, significant difference between WT and GK; ***P<0.01, significant difference
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Fig. 2 Effect of RYGB on fluorescence intensity changes of insulin
and calcium. a Beta cells were imaged using confocal microscopy after
intracellular insulin was labeled with FITC and free Ca2+ was labeled
with fluo-4/AM. The red image shows the FITC channel, and the green
image shows the fluo-4/AM channel. The scale bars in the images
represent 8 μm. The fluorescence detection channel was set to the
following ranges: fluo-4/AM, 494–516 nm; FITC, 490–495 nm. b
Effect of RYGB on fluorescence intensity changes of insulin. c Effect
of RYGB on fluorescence intensity changes of calcium. RYGB in-
creased the fluorescence intensity changes in intracellular insulin and
intracellular free Ca2. *P<0.05, **P<0.01, significant difference
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RYGB. Thus, RYGB animal models could be applied
for exploring the therapeutic mechanism of RYGB.
Effect of RYGB on the Gene Expression Profile of Islets
The mechanism of RYGB treatment for diabetes is complex.
To identify meaningful clues among the complicated clues,
the gene expression profile of islets was analyzed. First,
comparing the GKO cohort with the GK cohort and the
WTO cohort with the WT cohort, 158 and 529 differentially
expressed genes, respectively, were identified (Fig. 1a)
based on the RYGB procedure. The differentially expressed
genes, including 337 upregulated genes and 348
downregulated genes, were analyzed using MAS 3.0. GO
mapping showed that these differentially expressed genes
were mainly associated with metabolic regulation because
biological regulation-, regulation of biological process-, and
metabolism-related genes accounted for a large proportion
(up to 49.6 %) (Fig. 1b). The data suggested that the RYGB
procedure led to the creation of a new metabolic environ-
ment, and in islets, the expression of genes that were pri-
marily related to metabolic regulation was adjusted to adapt
to the new metabolic environment. Furthermore, with regard
to the impact of RYGB on Goto-Kakizaki rats and Wistar
rats, 30 differentially expressed genes were identified. The
30 genes were the result of the RYGB procedure. Next, to
identify which of the 30 genes were associated with diabe-
tes, genes that were differentially expressed between diabet-
ic rats and healthy rats were considered. Comparing the GK
cohort with the WT cohort, 469 differentially expressed
genes were identified (Fig. 1a) due to differences between
diabetic rats and healthy rats. After comprehensive compar-
ison, 13 genes (Amy1a, Rab30, Tff2, Ankrd57, B4galt5,
Birc3, Ccl2, Cks2, Cxcl10, Hmox1, Mdm2, Pcf1, and Tifa)
of the 30 differentially expressed genes were selected
(Fig. 1c). The data suggested that the 13 differentially
expressed genes were closely related to the RYGB proce-
dure and diabetes metabolism. The biological process and
molecular function of the 13 genes were further analyzed by
gene ontology. Regarding biological process, the genes pri-
marily participated in processes of metabolism, Ca2+ ho-
meostasis, and the regulation of cellular proliferation.
Regarding molecular functions, the genes were mainly re-
lated to growth factor activity, hormone activity, and metal
ion binding. The gene expression profile of islets showed
that differentially expressed genes related to Ca2+ signaling,
cellular proliferation, and hormones were closely associated
with the effect of the RYGB procedure and diabetes
metabolism.
Effect of RYGB on Gastrointestinal Hormone Levels
RYGB was observed to change the levels of hormones.
Comparing the WT cohort with the GK cohort, the level of
ghrelin was higher in the GK cohort. Comparing operation
cohorts with control cohorts, the level of ghrelin was higher
in control cohorts (Table 2). Thus, RYGB decreased the
levels of ghrelin. Comparing the WT cohort with the GK
cohort, the level of active GLP-1 (7–36) was higher in the
WT cohort. Comparing operation cohorts with control co-
horts, the level of GLP-1 was higher in operation cohorts
(Table 2). Thus, RYGB increased the level of active GLP-1.
Taken together, we found that RYGB changed the levels of
hormones 4 weeks after RYGB. RYGB could increase the
level of active GLP-1 (7–36) and decrease the level of
ghrelin in rats 4 weeks after RYGB.
Effect of RYGB on Intracellular Insulin and Calcium
RYGB may enhance intracellular insulin secretion and
changes in free Ca2+ concentration. When intracellular in-
sulin is labeled with FITC and intracellular free Ca2+ is
labeled with fluo-4/AM, the fluorescence intensity of insulin
and Ca2+ may indirectly reflect the concentration of intra-
cellular insulin and intracellular free Ca2+ (Fig. 2a). Com-
paring the GK cohort with the WT cohort, the fluorescence
intensity changes in insulin and Ca2+ were higher in the WT
cohort [insulin (percentage): WT, 8.02±0.53 vs. GK, 5.97±
0.22, n=19, P<0.01; calcium (percentage): WT, 7.44±0.89
vs. GK, 3.23±0.73, n=19, P<0.01; Fig. 2b, c]. The data
showed that changes in the concentration of intracellular
insulin and Ca2+ in diabetic rats were lower than those in
healthy rats. Comparing operation groups with control
groups, the fluorescence intensity changes in insulin and
Table 3 Effect of RYGB on the electrophysiology of calcium channels
WT WTO GK GKO
L-type (pA/pF) 6.01±2.08 6.62±2.09 11.23±3.80** 11.54±3.42
T-type (pA/pF) 2.13±0.57 2.01±0.50 3.81±0.90** 4.10±0.99
SOC (pA/pF) 7.44±1.98 10.12±1.76*** 9.27±1.92 14.35±2.04*
Values represent the mean±SD of n=18
*P<0.01, significant difference between GKO and GK; **P<0.01, significant difference between WT and GK; ***P<0.01, significant difference
between WTO and WT
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Ca2+ were higher in operation cohorts [insulin (percentage):
WTO, 10.81±0.93 vs. WT, 8.02±0.53, n=19, P<0.01;
GKO, 8.20±0.47 vs. GK, 5.97±0.22, n=19, P<0.01; calci-
um (percentage): WTO, 10.01±1.52 vs. WT, 7.44±0.89, n=
19, P<0.05; GKO, 5.81±0.76 vs. GK, 3.23±0.73, n=19, P
<0.01; Fig. 2b, c]. These results implied that RYGB
increased intracellular Ca2+ signaling and improved the
function of beta cells 4 weeks after RYGB. A significant
correlation at the 0.05 level was found between insulin
secretion and intracellular free Ca2+ change after RYGB
(WTO, Pearson’s correlation coefficient, r=0.998, P=0.031;
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Fig. 3 Effect of RYGB on
calcium channels. a Ramp
depolarization potential-
activated voltage-dependent
Ca2+ influx. The T-type
voltage-dependent Ca2+
channel (VDCC) opened at
−50 mV membrane potential.
The L-type VDCC opened with
an increase in membrane
potential and peaked at 0 mV, as
observed by the twin peak
pattern. b Effect of RYGB on
L-type VDCC current density. c
Effect of RYGB on T-type
VDCC current density. L-type
and T-type VDCC current
densities in the GK cohort were
higher than were those in the
WT cohort. RYGB did not alter
L-type or T-type VDCC current
densities. d The stored operated
calcium (SOC) current changed
over time to −100 mV. The
curve reflects SOC channel
activation, deactivation, and
inactivation. e Effect of RYGB
on SOC current density. RYGB
enhanced SOC current density.
**P<0.01, significant
difference
J Gastrointest Surg (2013) 17:1073–1083 1079
The data showed that intracellular free Ca2+ was closely
related to insulin secretion after RYGB. The increase in intra-
cellular free Ca2+ triggered by RYGB played an important role
in the functional improvement of beta cells.
Effect of RYGB on Calcium Channels
RYGB may enhance SOC activity. Comparing the GK co-
hort with the WT cohort, L-type and T-type VDCC current
densities were higher in the GK cohort. L-type and T-type
VDCC current densities in the operation cohorts were not
significantly different compared to control groups (Table 3,
Fig. 3b, c). However, SOC current densities were similar
between the WTcohort and the GK cohort. The SOC current
densities in the operation cohorts were significantly higher
than were those of control cohorts (Table 3, Fig. 3e). RYGB
enhanced SOC activity but did not alter VDCC activity
4 weeks after RYGB. Thus, RYGB primarily increased
changes in intracellular free Ca2+ through increasing SOC
activity.
Effects of RYGB on the Morphology of Islets and Beta
Cells
RYGB may promote the differentiation of primitive cells
into islets and improve the function of beta-cells. (1) The
morphology of islets was studied using optical microscopy.
In the WT cohort, the shape of the islets was regular and
uniform. The internal structure of the islets was normal, with
alpha cells distributed marginally and beta cells distributed
centrally. In the GK cohort, the shapes of the islets were
irregular and non-uniform. The internal structure of the
islets was disorganized. Small islets were occasionally ob-
served. Comparing operation cohorts with control cohorts, a
large number of small islets were present in operation co-
horts. The small islets only contained 8–24 cells (two-di-
mensional cross section), and it was difficult to distinguish
the cell type (Table 4, Fig. 4). Thus, RYGB promoted the
differentiation of primitive cells into new islets 4 weeks after
RYGB. (2) The morphology of beta cells was studied using
transmission electron microscopy. Beta cells can store
secreted products in vesicles. There were two types of
secretory vesicles in beta cells: large dense-core vesicles
(LDCVs) and synaptic-like microvesicles. LDCVs are crit-
ical for the transport and storage of insulin. The functional
ability of beta cells to synthesize and secrete insulin can
indirectly be evaluated through the measurement of the area
of the vesicles. In the WT cohort, the morphologic features
of LDCVs were consistent, and LDCVs were abundant. In
the GK cohort, there were few LDCVs in most beta cells.
The images showed that most beta cells were dysfunctional.
There was no significant difference between the WTO co-
hort and WT cohort. Comparing the GKO cohort with the
GK cohort, it was clear that the secretory vesicles were
increased in the GKO cohort. LDCVs were increased by
53.0 % after RYGB (Table 4, Fig. 4). Thus, RYGB im-
proved the function of beta cells 4 weeks after RYGB.
Discussion
RYGB has a novel therapeutic value for type 2 diabetes.
However, the therapeutic mechanism remains unclear.
Using an animal model, this study explored the therapeutic
mechanism of RYGB in diabetes.
First, an RYGB animal model was established. Then, the
therapeutic efficacy of animal model was evaluated. The
results confirmed that the model could be applied for ex-
ploring the therapeutic mechanism of RYGB.
Next, the therapeutic mechanism of RYGB in diabetes
was explored. First, the gene expression profile of islets was
analyzed. The gene expression profile can show changes in
genome-wide expression. And the physiological dysfunc-
tion of islets is the basis of diabetes. Thus, valuable infor-
mation can be acquired through studying the gene
expression profiles of islets. The result showed that after
RYGB, a new metabolic environment was present, and the
gene expression in islets was changed to adapt to the new
metabolic environment. Furthermore, 13 differentially
expressed genes that were found were closely related to
the RYGB procedure and diabetes metabolism. And the
molecular functions and biological process of the genes
Table 4 Effect of RYGB on islets and LDCVs
Small islets All islets Small islet ratio (%) LDCVs Percentage
WT 7 162 4.3 268 –
WTO 32 196 16.3 272 1.5 %
GK 19 185 10.3 166 –
GKO 52 212 24.5 254 53.0 %
The number of islets is the sum of ten sections for each group. Small islets were selected based on their area. The selection criterion for small islets
was area ≥1,000 μm2 . The number of LDCVs was calculated in fixed areas and is the sum of ten images for each group
LDCVS large dense-core vesicles, percentage=(LDCVs of operation cohort−LDCVs of control cohort)/LDCVs of operation cohort
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were mainly related to hormones, calcium signals, and cel-
lular proliferation by gene ontology analysis. 22–27 Further
research effects of RYGB on hormones, calcium, and cellu-
lar morphology could provide more information.
As messengers that transmit information, hormones play
an important regulatory role in the physiological processes
of the body. Insulin is an important factor that affects the
balance of the body’s glucose metabolism. The results
showed that RYGB increased serum insulin levels.
Furthermore, HOMA-β was used to evaluate the level of
insulin secretion.28 HOMA-β in diabetic rats increased after
RYGB. These findings suggested that the underlying thera-
peutic mechanism of RYGB was enhanced insulin secretion.
Previous studies have also reported that RYGB leads to a
marked improvement in glucose control, in which gastroin-
testinal hormones play a role.15 Additionally, researchers
have proposed various hypotheses regarding gastrointestinal






Fig. 4 Effect of RYGB on the
morphology of islets and beta
cells. Sections were observed
by OM. The islets were regular
in shape and size in the WT
cohort. The islets were irregular
in shape and size in the GK
cohort. At 4 weeks after RYGB,
small islets were present in
operation cohorts. Ultra-thin
sections of islets were viewed
by TEM. Secretory vesicles:
LDCVs were abundant in beta
cells of the WT cohort. LDCVs
were relatively scarce in most
beta cells of the GK cohort. At
4 weeks after RYGB, LDCVs
were more abundant in beta
cells of operation cohorts. The
scale bars in the images
represent 20 μm and 500 nm.
OM optical microscopy, TEM
electron microscopy
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hormones, including ghrelin and GLP-1. Ghrelin is an endog-
enous ligand of the growth hormone secretagogue
receptor.31,32 Ghrelin can be expressed in alpha cells and beta
cells of islets, and it is not only directly involved in insulin
secretion but also determines the differentiation of islet cells.
GLP-1 is an important and extensively studied incretin.33,34
GLP-1 can stimulate insulin secretion and enhance beta cell
proliferation. A synthetic analogue of GLP-1 (exendin-4) has
been successfully introduced to treat diabetes patients.35 Our
results showed that RYGB promoted the secretion of GLP-1
and decreased ghrelin levels. Based on the effects of RYGB
on the cellular morphology and hormone levels, and the
production location of ghrelin and GLP-1, we speculated that
promoting cellular proliferation and improving cellular func-
tion are two of the roles that gastrointestinal hormones play in
the therapeutic mechanism of RYGB in diabetes.
And previous researchers have proposed that ghrelin and
GLP-1 regulate insulin secretion by affecting the calcium
signaling pathway. Intracellular free Ca2+ not only triggers
secretion36 but is also involved in the regulation of
exocytosis.37,38 Fluorescence labeling may monitor the con-
tinuous changes in concentration. Fluo-4 is a highly specific
Ca2+ fluorescence probe, and changes in its fluorescence
intensity can sensitively reflect changes in the concentration
of intracellular free Ca2+. Under appropriate conditions, FITC
can bind to insulin. The changes in intracellular fluorescence
intensity indirectly indicate the cells’ ability to secrete insulin.
Labeling calcium and insulin can effectively reflect the calci-
um signals and insulin secretion in beta cells. The results
showed that RYGB increased the concentration of intracellu-
lar free Ca2+ and insulin secretion, and the change in intracel-
lular free Ca2+ was closely related to insulin secretion after
RYGB. Thus, Ca2+ signal played an important role in the
RYGB effect on diabetes. RYGB caused an increase in the
concentration of intracellular free Ca2+, which promoted in-
sulin secretion. Our group further studied Ca2+ channels and
attempted to elucidate the mechanism through which RYGB
increased intracellular free Ca2+. The intracellular free Ca2+
concentration is maintained at a low level. Calcium influx
across the cell membrane via a Ca2+ channel increases the
Ca2+ concentration within the cytosol. The Ca2+ channels in
beta cell membranes are mainly VDCCs, and SOC also
exists.39 SOC may be involved in Ca2+ signal transmission.40
The result showed that RYGB had little effect on VDCC
activity. However, RYGB significantly enhanced SOC activ-
ity. The finding not only elucidates the mechanism through
which RYGB elevated intracellular free Ca2+ but also pro-
vides new ideas for the drug treatment of diabetes.
Cellular structure and function are intricately related. After
RYGB, the number of small islets and secretory vesicles was
increased. The results supported that RYGB could promote the
differentiation of primitive cells into islets cells, and improve
the function of beta cells. RYGB increased the quantity and
improved the quality of insulin secretion cells. These morpho-
logical changes were the result of hormone adjustment and
calcium signal changes. At the same time, these morphological
changes were the basis of insulin secretion improvement.
In summary, we hypothesize that RYGB led to the crea-
tion of a new metabolic environment and triggered a series
of changes, primarily in hormone levels and Ca2+ signaling,
to adapt to this new environment. These adjustments further
induced the cellular differentiation of primitive cells into
islets cells and improved the function of beta cells. RYGB
increased the quantity and improved the quality of insulin
secretion cells. RYGB ultimately led to enhancing insulin
secretion to treat diabetes. The study of the mechanism
through which RYGB alleviates type 2 diabetes is a critical
theoretical and clinical research endeavor. The study is a
novel approach to determining the mechanism of RYGB.
There are more parallel and intersecting comparisons be-
tween diabetic rats and healthy rats and the operation cohort
and control cohort.
However, the animal model cannot be fully compliant
with human type 2 diabetes characteristics. And it is difficult
to obtain a large number of high-quality islets. The long-
term effects of RYGB have not been explored. Thus, our
next study will aim to elucidate the mechanism of long-term
effects of RYGB on rats.
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